ALPHE.PA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ALPHE.PAPherecydes Pharma S.A.	$2.00	-0.50%	$16M	—
ALACT.PAActicor Biotech SAS	$0.25	+0.00%	$4M	—
ALHYG.PAHybrigenics S.A.	$0.01	+4.04%	$4M	—
ALQGC.PAQuantum Genomics S.A.	$0.07	+0.00%	$5M	—
ALTER.PATheradiag S.A.	$1.26	-4.91%	$17M	—
ALVET.PATheraVet S.A.	$0.08	+0.00%	$10M	—
APM.PAAptorum Group Limited	$3.21	+0.00%	$9M	—

Source: Financial Modeling Prep · peers by sector/industry

Pherecydes Pharma S.A.

Pherecydes Pharma S.A. focuses on developing antimicrobial treatments by leveraging bacteriophage viruses, also known as phages. The company's pipeline includes a range of therapeutic options: phages engineered to combat Staphylococcus aureus in bone/joint and diabetic foot ulcer infections; phages targeting Pseudomonas aeruginosa for complicated urinary tract infections; and phages designed to address Escherichia coli in respiratory tract infections. The firm was founded in 2006 and is headquartered in Romainville, France.

www.pherecydes-pharma.com

Employees: 29
IPO / List date: Feb 5, 2021
HQ: FR

Held by traders on TradeandTell

No one on the platform currently holds ALPHE.PA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ALPHE.PA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ALPHE.PA yet.